Monday, June 15, 2026 · 09:00 ET · Week 24 of launch
Sonarex brand dashboard.
4 months post-launch · 48 Rx YTD · funnel velocity +12% WoW · 2 content gaps require action · 1 competitive alert.
HCP journey funnel
200-HCP cohort · stage distribution as of today
87
Non-prescriber
54
Aware
32
Trial
19
Adopter
8
Advocate
✓ Aware → Trial transition velocity is +12% vs last week · Trial → Adopter is +4% · Adopter → Advocate +2%
Content gap signals
CNS sequencing discussion framework
Surfaced at 2026-05-15 ad-board by 4 KOLs. Currently no MLR-approved asset to address. ACE NBA has wanted to recommend this asset 7 times in 30 days but can't.
→ Get MLR Q3 submission on the calendar.
KOL-facing payer access toolkit
Ad-board feedback: KOLs want clear payer-engagement materials. Currently sales aid + dossier exist but no integrated KOL-facing toolkit.
→ Devon + market access team to scope.
Competitive alerts
BMS Q1 2026 earnings — Krazati $112M (+38% YoY)
Krazati gaining share. Mirati legacy + BMS sales force effective. Particularly strong in academic centers. Field intel suggests 3 of 5 our Q1 Lumakras → Sonarex displacements were because the HCP was already comparing vs Krazati, not Lumakras.
→ Suggest Q3 ad-board theme: “Why our switch story isn't Lumakras → Sonarex; it's a 3-way conversation.”
Doxsona intel score: 7 · Detected 2026-04-22
- ESMO 2026 (9/18) divarasib readout — flagged for monitoring, ACE will alert when divulged.
Segment velocity
- +
MA KOL
9 of 15 in Advocate (60%)
- +
Commercial Ad Board
11 of 15 in Adopter+ (73%)
- +
Go-Get
5 of 20 converting (25% Y1 target: 60%)
- +
High Prescriber
Trial → Adopter slowing
- 0
Academic Affiliated
Steady
- -
Community
Aware → Trial gap widening
Channel performance
- Field rep · NBA acceptance74%+6 pp
- MSL · ad-board attendance92%+0
- Email seq 1 · open rate38%+4 pp
- Email seq 2 · click rate11%-3 pp
- Banner CTR · brain mets0.42%+0.08 pp
- sonarex-hcp.com unique HCPs3,184WoW +12%
KOL coverage status
Y1 target: 12 of 20